Bulletin
Investor Alert

Topics

Biotechnology

Video

Gain of Function: The Search for Covid's Origins Sparks Renewed Debate

  • Gain of Function: The Search for Covid's Origins Sparks Renewed Debate Gain of Function: The Search for Covid's Origins Sparks Renewed Debate 5:22
    Theranos Founder Elizabeth Holmes on Trial: What to Expect Theranos Founder Elizabeth Holmes on Trial: What to Expect 11:35
    How 'female Viagra' could disrupt $6 bln sexual dysfunction market How 'female Viagra' could disrupt $6 bln sexual dysfunction market 2:47
    What Happens to a Biotech Stock After a Vaccine is Developed? What Happens to a Biotech Stock After a Vaccine is Developed? 2:14
1:47 p.m. Today - By Ciara Linnane
J&J says booster shot greatly improves its COVID-19 vaccine’s efficacy as experts await FDA decisionJohnson & Johnson became the latest COVID-19 vaccine maker to offer an update on booster doses Tuesday, when it said data from a Phase 3 trial and the real world found protection against hospitalization and death is greatly improved by a booster jab of its one-shot vaccine.
1:29 p.m. Today - By MarketWatch Automation
1:19 p.m. Today - By MarketWatch Automation
1:16 p.m. Today - By MarketWatch Automation
1:14 p.m. Today - By MarketWatch Automation
1:01 p.m. Today - By MarketWatch Automation
1:00 p.m. Today - By MarketWatch Automation
1:00 p.m. Today - By MarketWatch Automation
1:00 p.m. Today - By MarketWatch Automation
1:00 p.m. Today - By MarketWatch Automation
12:56 p.m. Today - By MarketWatch Automation
12:46 p.m. Today - By MarketWatch Automation
12:41 p.m. Today - By MarketWatch Automation
12:40 p.m. Today - By MarketWatch Automation
12:38 p.m. Today - By MarketWatch Automation
12:36 p.m. Today - By MarketWatch Automation
12:32 p.m. Today - By MarketWatch Automation
7:49 a.m. Today - By MarketWatch Automation
7:42 a.m. Today - By Andrew Keshner
‘I’m a firm believer in science, but I'd still like to wait’: Pfizer's vaccine results for kids might not lead to quick vaccinations4 in 10 parents of children ages 5 to 11 say they’ll take a 'wait and see' approach before they have their kids vaccinated, according to a survey from the Kaiser Family Foundation.
6:46 a.m. Today - By MarketWatch Automation
1:29 p.m. Sept. 20, 2021 - By MarketWatch Automation
1:19 p.m. Sept. 20, 2021 - By MarketWatch Automation
1:16 p.m. Sept. 20, 2021 - By MarketWatch Automation
1:13 p.m. Sept. 20, 2021 - By MarketWatch Automation
1:01 p.m. Sept. 20, 2021 - By MarketWatch Automation
1:00 p.m. Sept. 20, 2021 - By MarketWatch Automation
1:00 p.m. Sept. 20, 2021 - By MarketWatch Automation
1:00 p.m. Sept. 20, 2021 - By MarketWatch Automation
12:59 p.m. Sept. 20, 2021 - By MarketWatch Automation
12:56 p.m. Sept. 20, 2021 - By MarketWatch Automation
12:46 p.m. Sept. 20, 2021 - By MarketWatch Automation
12:45 p.m. Sept. 20, 2021 - By Philip van Doorn
Here are the worst-performing U.S. stocks as the Evergrande crisis rattles investorsDebt-market rumblings in China are affecting U.S. stocks, at least for now.
12:41 p.m. Sept. 20, 2021 - By MarketWatch Automation
12:40 p.m. Sept. 20, 2021 - By MarketWatch Automation
12:38 p.m. Sept. 20, 2021 - By MarketWatch Automation
12:36 p.m. Sept. 20, 2021 - By MarketWatch Automation
12:35 p.m. Sept. 20, 2021 - By Ciara Linnane
Upbeat result of COVID-19 vaccine trial in 5- to 11-year-olds tempered as U.S. daily death rate tops 2,000 for first time since March 1Positive results from a trial of the COVID-19 vaccine developed by Pfizer and German partner BioNTech in children 5 to 11 years old was tempered Monday by a rising average death rate, with the U.S. now seeing more than 2,000 fatalities a day for the first time since March 1.
12:32 p.m. Sept. 20, 2021 - By MarketWatch Automation
3:51 a.m. Sept. 20, 2021 - Barrons.com
Pills to Battle Covid Are Coming. These Firms Stand to Gain. Merck, Pfizer, and the Atea Pharmaceuticals each expect Phase 3 data on an oral Covid-19 antiviral in the coming months.
3:47 a.m. Sept. 20, 2021 - By Jaimy Lee
FDA panel recommends Pfizer’s COVID-19 booster for 65 and older, but not for the general publicA group of advisors to the Food and Drug Administration on Friday reframed a proposed approval of BioNTech and Pfizer's COVID-19 booster for the general population, and it instead recommended authorization of an additional dose of the vaccine to people at least 65 years old and those at high risk for severe disease.
Browse topics:

Filter results by

Industry

Biotechnology (514)

Health-care (268)

Pharmaceuticals (246)

Medical Products (235)

Software (74)

Internet (68)

Location

Us (555)

Europe (146)

Asia Pacific (116)

Eu (114)

China (100)

Japan (61)

Issue

General (402)

Economy (77)

Commodities (62)

Market News (61)

Markets/exchanges (61)

Opinion (61)

Link to MarketWatch's Slice.